Αρχική World News Promising Results Observed with Front-line Sintilimab Plus a Bevacizumab Biosimilar in Patients...

Promising Results Observed with Front-line Sintilimab Plus a Bevacizumab Biosimilar in Patients with Advanced HCC

Sintilimab, which has been approved in China for the treatment of Hodgkin’s disease, in combination with a bevacizumab biosimilar as first-line treatment of patients with advanced hepatocellular carcinoma (HCC) significantly improved survival compared to sorafenib, according to findings presented at the ESMO Asia Virtual Congress 2020, held 20 to 22 November 2020.

Zhenggang Ren of the Department of Hepatic Oncology, Zhongshan Hospital of Fudan University in Shanghai, China, presented data from the phase III efficacy part of the randomised, open-label, multicentre phase II/III ORIENT-32 (NCT03794440) study evaluating sintilimab plus a bevacizumab biosimilar versus sorafenib as first-line treatment for advanced HCC. The phase II part of the study demonstrated acceptable safety with the combination.

ORIENT-32 enrolled patients with unresectable or metastatic HCC who were naive for systemic HCC treatment. In phase III part, following 2:1 randomisation, 380 patients were treated with sintilimab at 200 mg i.v. every 3 weeks plus a bevacizumab biosimilar at 15 mg/kg i.v. every 3 weeks and 191 patients were treated with oral sorafenib at 400 mg twice daily. Stratification factors included macrovascular invasion and/or extrahepatic metastasis (presence versus absence), baseline alpha fetoprotein level (< 400 versus ≥400 ng/mL) and ECOG performance status (0 versus 1).

The primary endpoints were overall survival (OS) and progression-free survival (PFS) by independent radiographic review committee (IRRC) per RECIST v1.1.

Combination of sintilimab plus bevacizumab biosimilar showed significantly improved survival, thus meeting the study primary endpoints

Among the patients enrolled by data cut-off on 15 August 2020, the baseline characteristics were well balanced; the majority (94.2%) of patients had hepatitis B infection and 4.2% of patients had Child-Pugh B status of chronic liver disease.

With median follow-up of 10.0 months, median OS was significantly longer with the sintilimab plus bevacizumab biosimilar combination than with sorafenib, and the combination setting demonstrated a 43.1% decreased risk of all-cause death; median OS was not estimable (NE) compared to 10.4 months, respectively (hazard ratio [HR] 0.569; 95% confidence interval [CI] 0.431-0.751; p < 0.0001).

Similarly, improved PFS was also demonstrated, with a 43.5% decreased risk of progression assessed by IRRC per RECIST v1.1; median PFS with the combination was 4.6 months compared to 2.8 months with sorafenib (HR 0.565; 95% CI 0.455-0.701, p < 0.0001).


Overall survival and progression-free survival, the primary endpoints in the ORIENT-32 study.

© Zhenggang Ren.

Overall benefit favoured the combination over sorafenib consistently across all the subgroups evaluated.

Efficacy-evaluable patients demonstrated a confirmed objective response rate (ORR; by IRRC per RECIST v1.1) of 20.5% (95% CI 16.5-25.1) with the combination versus 4.1% (95% CI 1.7-8.2) with sorafenib.

Among patients receiving at least one drug dose, any grade treatment related adverse events (TRAEs) occurred in 88.7% of patients receiving the combination versus 93.5% of sorafenib-treated patients. Grade 3/4 TRAEs were reported in 33.7% and 35.7% of patients, respectively.


According to the authors, sintilimab plus a bevacizumab biosimilar showed significant improvements in clinical benefits compared to sorafenib, as first-line treatment of patients with advanced hepatocellular carcinoma.

Funding for this study was reported from Innovent Biologics, Inc.


LBA2 – Ren Z, Fan J, Xu J, et al. Sintilimab plus bevacizumab biosimilar vs sorafenib as first-line treatment for advanced hepatocellular carcinoma (ORIENT-32). ESMO Asia Virtual Congress 2020 (20-22 November).



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...

Καρκίνος: Ευεργετική για τους καρκινοπαθείς η άσκηση

Σημαντικά ωφέλη προσφέρει η άσκηση, ακόμη και σε ασθενείς με καρκίνο. Οι περισσότεροι ασθενείς αγνοούν τα οφέλη που μπορεί να έχει γι’ αυτούς η συχνή...

Prostate Cancer

The article is provided by Scientific Communications Officer of NIPD Genetics, Ms Marina Charitou (MSc) Prostate Cancer Awareness Prostate cancer is the second most common cancer...
- Advertisment -

Ροή Ειδήσεων

Discovering the BRCA2 gene – 25 years on

A breast cancer cell. Credit: LRI EM Unit. 25 years ago, a team of our scientists were celebrating. Their risky strategy had paid off. “You...

Newly Developed RSClin Provides Prognostic Information in HR-positive, HER2-negative Early Breast Cancer

The online RSClin tool incorporating clinical-pathological data and the results of a 21-gene recurrence score (RS) was able to estimate the risk of distant...

Embracing Bravery When You Have a Genetic Cancer Disease

Emily Pinto Billcheck is a licensed social worker with experience in the mental health field. She is a von Hippel-Lindau (VHL) patient who inherited VHL from her...

Chemotherapy Administered for the First Diagnosed Testicular Cancer Reduces the Risk of Metachronous Contralateral Testicular Cancer Occurrence

Patients aged less than 30 years upon diagnosis of testicular cancer and those treated with surgery only are at higher risk of developing a...

New Research Looks for More Effective Breast Cancer Treatments for Black Women

Breast cancer affects people across all different backgrounds, but Black women in particular are more apt to get aggressive forms of the disease. They’re...

Palbociclib Plus Endocrine Therapy Does Not Improve PFS over Capecitabine in HR-positive, HER2-negative Aromatase Inhibitor Resistant Metastatic Breast Cancer

Although patients with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative, aromatase inhibitor resistant metastatic breast cancer maintained quality of life...